Recent advances in therapies for primary myelofibrosis

Recent advances in therapies for primary myelofibrosis

Primary myelofibrosis (PMF), polycythemia vera (PV) and essential thrombocythemia (ET) form the classical BCR-ABL1-negative myeloproliferative neoplasms (MPNs) that are driven by a constitutive activation of JAK2 signaling. PMF as well as secondary MF (post-ET and post-PV MF) are the most aggressive...

Bibliografske podrobnosti
Main Authors:	Vainchenker, W, Yahmi, N, Havelange, V, Marty, C, Plo, I, Constantinescu, SN
Format:	Journal article
Jezik:	English
Izdano:	Faculty Opinions 2023

Podobne knjige/članki

Recent advances in understanding myelofibrosis and essential thrombocythemia [version 1; referees: 2 approved]
od: William Vainchenker, et al.
Izdano: (2016-04-01)

Therapeutic activity of GARP:TGF-β1 blockade in murine primary myelofibrosis
od: Lecomte, S, et al.
Izdano: (2023)

ADVANCED THERAPY IN PATIENTS WITH PRIMARY AND POSTPOLYCYTHEMIC MYELOFIBROSIS
od: A. N. Alekseeva, et al.
Izdano: (2017-07-01)

Molecular pathogenesis of myeloproliferative neoplasms: Where do we stand in 2023?
od: Havelange, V, et al.
Izdano: (2023)

Recent developments in myelofibrosis
od: Mesa RA, et al.
Izdano: (2012-07-01)

SRSF2-P95H decreases JAK/STAT signaling in hematopoietic cells and delays myelofibrosis development in mice
od: Willekens, C, et al.
Izdano: (2023)

Updated recommendations on the use of ruxolitinib for the treatment of myelofibrosis
od: Timothy Devos, et al.
Izdano: (2022-01-01)

Primary myelofibrosis L.
od: L. M. Meshcheryakova, et al.
Izdano: (2014-07-01)

Primary myelofibrosis L.
od: L. M. Meshcheryakova, et al.
Izdano: (2014-07-01)

Primary myelofibrosis in rheumatic diseases
od: Vladimir Ivanovich Vasilyev, et al.
Izdano: (2013-04-01)

JAK inhibitors for the treatment of myeloproliferative neoplasms and other disorders [version 1; referees: 2 approved]
od: William Vainchenker, et al.
Izdano: (2018-01-01)

Treatment of primary myelofibrosis
od: Şinasi Özsoylu
Izdano: (2009-12-01)

Editorial: recent advances in molecular and structural endocrinology
od: De Meyts, P, et al.
Izdano: (2023)

Advances in management of primary myelofibrosis and polycythaemia vera: Implications in clinical practice
od: Shanti Amé, et al.
Izdano: (2023-08-01)

Hemostasis in patients with primary myelofibrosis treated with ruxolitinib
od: O. G. Golovina, et al.
Izdano: (2024-11-01)

A phase II study of vorinostat (MK-0683) in patients with primary myelofibrosis and post-polycythemia vera myelofibrosis
od: Christen L. Andersen, et al.
Izdano: (2014-01-01)

IRON CHELATION THERAPY WITH DEFERASIROX IN THE MANAGEMENT OF IRON OVERLOAD IN PRIMARY MYELOFIBROSIS
od: Elena Maria Elli, et al.
Izdano: (2014-05-01)

Evidence for prevention of renal dysfunction associated with primary myelofibrosis by cytoreductive therapy
od: Yasutaka Fukuda, et al.
Izdano: (2019-11-01)

Mutational spectrum defines primary and secondary myelofibrosis
od: Ken I. Mills, et al.
Izdano: (2014-01-01)

Splenic Marginal Zone Lymphoma with Prominent Myelofibrosis Mimicking Triple-Negative Primary Myelofibrosis
od: Miyuki Tsutsui, et al.
Izdano: (2019-11-01)

Possibilities of targeted therapy for myelofibrosis: Moscow experience
od: O. Yu. Vinogradova, et al.
Izdano: (2022-11-01)

CD146+ bone marrow osteoprogenitors increase in the advanced stages of primary myelofibrosis
od: Claudio Tripodo, et al.
Izdano: (2009-01-01)

Targeted deep sequencing in primary myelofibrosis
od: Ayalew Tefferi, et al.
Izdano: (2016-12-01)

Calreticulin mutations in Chinese with primary myelofibrosis
od: Bing Li, et al.
Izdano: (2014-11-01)

Is it primary myelofibrosis or chronic megakaryocytic leukemia?
od: Marshall A. Lichtman
Izdano: (2022-03-01)

Focus on Osteosclerotic Progression in Primary Myelofibrosis
od: Mariarita Spampinato, et al.
Izdano: (2021-01-01)

Primary Myelofibrosis with Mesenteric Extramedullary Haematopoiesis
od: Saurabh Kumar, et al.
Izdano: (2018-12-01)

Primary myelofibrosis: current therapeutic options
od: Paula de Melo Campos

Myelofibrosis and Pancytopenia Associated With Primary Hyperparathyroidism
od: Remya Rajan, MD, et al.
Izdano: (2021-01-01)

Does angiogenesis matter in primary myelofibrosis?
od: Paulo Vidal Campregher
Izdano: (2014-10-01)

Patients with primary myelofibrosis: treatment and quality of life
od: L. M. Meshcheryakova, et al.
Izdano: (2014-07-01)

Patients with primary myelofibrosis: treatment and quality of life
od: L. M. Meshcheryakova, et al.
Izdano: (2014-07-01)

Advances in myelofibrosis: a clinical case approach
od: John O. Mascarenhas, et al.
Izdano: (2013-10-01)

Long-term results of splenectomy in primary myelofibrosis
od: L. M. Meshcheryakova, et al.
Izdano: (2014-07-01)

Long-term results of splenectomy in primary myelofibrosis
od: L. M. Meshcheryakova, et al.
Izdano: (2014-07-01)

P1047: REAL-WORLD SAFETY OF RUXOLITINIB IN PATIENTS WITH INTERMEDIATE OR HIGH RISK OF PRIMARY MYELOFIBROSIS, POST-POLYCYTHEMIA VERA MYELOFIBROSIS OR POST-ESSENTIAL THROMBOCYTHEMIA MYELOFIBROSIS IN CHINA
od: Z. Xu, et al.
Izdano: (2022-06-01)

Evidence that prefibrotic myelofibrosis is aligned along a clinical and biological continuum featuring primary myelofibrosis.
od: Giovanni Barosi, et al.
Izdano: (2012-01-01)

Genetic Alterations of the Thrombopoietin/MPL/JAK2 Axis Impacting Megakaryopoiesis
od: Isabelle Plo, et al.
Izdano: (2017-09-01)

PB2173: THE EFFECT OF RUXOLITINIB THERAPY ON HEMOSTATIC PARAMETERS IN PATIENTS WITH PRIMARY MYELOFIBROSIS
od: Natalia Korsakova, et al.
Izdano: (2023-08-01)

P1015: THE EFFECT OF THERAPY ON THE COAGULATION ACTIVITY OF MICROPARTICLES IN PATIENTS WITH PRIMARY MYELOFIBROSIS
od: Natalia Silina, et al.
Izdano: (2023-08-01)